The phase 2/3 human clinical trial for a vaccine against coronavirus has been running smoothly in the country with no safety concerns so far, and the entire recruitment process of 1,600 volunteers for the Covishield vaccine trial has been completed across 17 trial sites by October 31, according to the Serum Institute of India (SII). Serum Institute, the world’s largest vaccine manufacturer by the number of doses produced, is working on several candidates for a vaccine against Covid-19, including one from AstraZeneca-Oxford University as well as developing its own.
*Please create a profile first to EARN & REDEEM points
No safety concerns related to the Covishield vaccine trial: Serum chief
We are building a board of industry expert to help us verify important news stories. If you would like to empanel yourself, please click here.